Search clinical trials for: deforolimus

Total 22 results

Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Lymphoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Angela Taber MD
The Miriam Hospital; Rhode Island Hospital; Memorial Hospital of Rhode Island; Roger...

Terminated

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

Non-Small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)

Metastatic or Locally Advanced Cancer
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)

Cancer, Advanced
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Terminated

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

Advanced Cancers
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Prostate Cancer

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors

United States
Merck Sharp & Dohme LLC

Completed

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Breast Cancer | Breast Neoplasms
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Hematologic Malignancies | Myeloid Metaplasia

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)

Glioblastoma | Malignant Glioma | Gliosarcoma

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Sarcoma | Cancer
Merck Sharp & Dohme LLC

Completed

Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Endometrial Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Sarcoma
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Endometrial Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) (SUCCEED)

Metastatic Soft-Tissue Sarcomas | Metastatic Bone Sarcomas
Merck Sharp & Dohme LLC
University of Colorado, Denver; Memorial Sloan Kettering Cancer Center; H. Lee... and other collaborators

Completed

A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)

Solid Tumors
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Sarcoma, Soft Tissue | Osteosarcoma | Leiomyosarcoma | Liposarcoma | Metastases
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Solid Tumor
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Terminated

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Non-Small Cell Lung Cancer
The University of Texas Health Science Center at...
Merck Sharp & Dohme LLC

Withdrawn

Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States

3

Subscribe